Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CTNM Contineum Therapeutics	$5.96 +1.0%	$4.40	$3.35 ▼ $20.55	$152.64M	1.01	299,417 shs	262,492 shs
IMRX Immuneering	$3.37 -2.0%	$3.08	$1.00 ▼ $4.69	$123.79M	0.38	682,191 shs	271,417 shs
KPTI Karyopharm Therapeutics	$3.93 +3.1%	$4.38	$3.51 ▼ $16.95	$32.92M	0.28	225,958 shs	64,132 shs
THTX Theratechnologies	$3.16 +0.3%	$2.79	$1.12 ▼ $3.20	$144.84M	0.52	596,911 shs	709,739 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CTNM Contineum Therapeutics	+1.02%	+3.29%	+49.00%	+45.37%	-70.29%
IMRX Immuneering	-2.03%	-17.00%	-6.13%	+171.77%	+198.23%
KPTI Karyopharm Therapeutics	+3.15%	-9.66%	-14.75%	-46.60%	-73.50%
THTX Theratechnologies	+0.32%	-0.32%	+33.90%	+14.08%	+120.98%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CTNM Contineum Therapeutics	2.4926 of 5 stars	3.6	3.0	0.0	0.0	1.1	0.8	1.3
IMRX Immuneering	2.9174 of 5 stars	3.3	3.0	0.0	0.0	0.6	5.0	0.6
KPTI Karyopharm Therapeutics	3.4144 of 5 stars	3.4	0.0	0.0	4.6	0.6	2.5	0.6
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CTNM Contineum Therapeutics	3.17	Buy	$22.50	277.52% Upside
IMRX Immuneering	2.60	Moderate Buy	$13.25	293.18% Upside
KPTI Karyopharm Therapeutics	2.80	Moderate Buy	$37.40	851.65% Upside
THTX Theratechnologies	3.00	Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest KPTI, CTNM, IMRX, and THTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/16/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$27.00
7/3/2025	THTX Theratechnologies	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
6/20/2025	CTNM Contineum Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform
6/18/2025	IMRX Immuneering	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$8.00 ➝ $10.00
6/18/2025	IMRX Immuneering	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00
6/18/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/5/2025	IMRX Immuneering	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
5/19/2025	CTNM Contineum Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$25.00 ➝ $20.00
5/15/2025	CTNM Contineum Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$31.00 ➝ $31.00
5/13/2025	KPTI Karyopharm Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$34.00 ➝ $33.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CTNM Contineum Therapeutics	$50M	3.08	N/A	N/A	$7.66 per share	0.78
IMRX Immuneering	N/A	N/A	N/A	N/A	$1.33 per share	N/A
KPTI Karyopharm Therapeutics	$145.24M	0.23	N/A	N/A	($22.10) per share	-0.18
THTX Theratechnologies	$85.87M	1.69	N/A	N/A	($0.61) per share	-5.18

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CTNM Contineum Therapeutics	-$42.26M	-$1.97	N/A	N/A	N/A	N/A	-24.59%	-23.49%	8/12/2025 (Estimated)
IMRX Immuneering	-$61.04M	-$1.96	N/A	N/A	N/A	N/A	-119.22%	-99.22%	8/5/2025 (Estimated)
KPTI Karyopharm Therapeutics	-$76.42M	-$13.26	N/A	N/A	N/A	-43.99%	N/A	-35.95%	8/5/2025 (Estimated)
THTX Theratechnologies	-$8.31M	-$0.19	N/A	45.14	N/A	-10.85%	N/A	-9.83%	10/9/2025 (Estimated)

Latest KPTI, CTNM, IMRX, and THTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2025	Q2 2025	CTNM Contineum Therapeutics	-$0.56	N/A	N/A	N/A	$7.50 million	N/A
8/5/2025	Q2 2025	IMRX Immuneering	-$0.40	N/A	N/A	N/A	N/A	N/A
8/5/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.72	N/A	N/A	N/A	$37.92 million	N/A
7/9/2025	Q2 2025	THTX Theratechnologies	-$0.01	-$0.09	-$0.08	-$0.09	$24.30 million	$17,729.00 billion
5/14/2025	Q1 2025	CTNM Contineum Therapeutics	-$0.56	-$0.62	-$0.06	-$0.62	$7.50 million	N/A
5/12/2025	Q1 2025	KPTI Karyopharm Therapeutics	-$4.21	-$2.77	+$1.44	-$2.77	$35.12 million	$30.02 million
5/5/2025	Q1 2025	IMRX Immuneering	-$0.41	-$0.42	-$0.01	-$0.42	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
IMRX Immuneering	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A
THTX Theratechnologies	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CTNM Contineum Therapeutics	N/A	21.47	21.47
IMRX Immuneering	N/A	7.48	7.48
KPTI Karyopharm Therapeutics	N/A	1.33	1.28
THTX Theratechnologies	N/A	0.84	0.65

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CTNM Contineum Therapeutics	N/A
IMRX Immuneering	67.65%
KPTI Karyopharm Therapeutics	66.44%
THTX Theratechnologies	N/A

Insider Ownership

Company	Insider Ownership
CTNM Contineum Therapeutics	11.30%
IMRX Immuneering	22.90%
KPTI Karyopharm Therapeutics	2.98%
THTX Theratechnologies	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CTNM Contineum Therapeutics	31	25.87 million	22.95 million	N/A
IMRX Immuneering	60	35.99 million	27.75 million	Not Optionable
KPTI Karyopharm Therapeutics	380	8.64 million	8.38 million	Optionable
THTX Theratechnologies	140	45.98 million	N/A	Optionable

KPTI, CTNM, IMRX, and THTX Headlines

Recent News About These Companies

Theratechnologies (NASDAQ:THTX) Trading Down 0.3% - Here's What Happened

July 31 at 3:15 AM | marketbeat.com

AIGH Capital Management LLC Trims Position in Theratechnologies Inc. (NASDAQ:THTX)

July 22, 2025 | marketbeat.com

Theratechnologies (NASDAQ:THTX) Announces Quarterly Earnings Results

July 9, 2025 | marketbeat.com

Theratechnologies Reports Financial Results for the Second Quarter 2025

July 9, 2025 | globenewswire.com

Theratechnologies: Beyond GLP-1s - Is Tesamorelin's Exit A Sign Of New Metabolic Opportunities?

July 7, 2025 | seekingalpha.com

Future Pak to buy Theratechnologies for $254 million

July 4, 2025 | thepharmaletter.comT

Theratechnologies Stock (NASDAQ:THTX), Insider Trading Activity

July 3, 2025 | benzinga.com

Theratechnologies Inc. (THTX) - Yahoo Finance

July 3, 2025 | finance.yahoo.com

Theratechnologies Stock Short Interest Report | NASDAQ:THTX - Benzinga

July 3, 2025 | benzinga.com

Theratechnologies shareholders should take the deal, Research Capital says

July 3, 2025 | cantechletter.comC

Theratechnologies to be bought by CB Biotechnology for $254M

July 3, 2025 | msn.com

Theratechnologies to Announce Second Quarter 2025 Financial Results

July 3, 2025 | globenewswire.com

Theratechnologies' (THTX) Hold Rating Reaffirmed at Jones Trading

July 3, 2025 | marketbeat.com

Theratechnologies to be Acquired by Future Pak Affiliate

July 2, 2025 | tipranks.com

Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

July 2, 2025 | finance.yahoo.com

Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

July 2, 2025 | globenewswire.com

Theratechnologies Reports on its Annual Meeting of Shareholders

May 29, 2025 | globenewswire.com

Theratechnologies announces annual shareholder meeting

May 4, 2025 | uk.investing.com

Theratechnologies Presents Novel Data at ACTHIV 2025 Underscoring Importance of Managing Excess Visceral Abdominal Fat (EVAF) in People with HIV

May 2, 2025 | globenewswire.com

Theratechnologies: A High-Risk, High-Reward Speculation As Shares Trade At 39% Discount To Future Pak's $3.51-$4.50 Offer

April 18, 2025 | seekingalpha.com

Is Theratechnologies Inc. (THTX) the Best Rising Penny Stock to Buy According to Analysts?

April 18, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

KPTI, CTNM, IMRX, and THTX Company Descriptions

Contineum Therapeutics NASDAQ:CTNM

$5.96 +0.06 (+1.02%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$5.96 0.00 (0.00%)

As of 08/1/2025 06:33 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Immuneering NASDAQ:IMRX

$3.37 -0.07 (-2.03%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$3.42 +0.05 (+1.60%)

As of 08/1/2025 07:50 PM Eastern

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.

Karyopharm Therapeutics NASDAQ:KPTI

$3.93 +0.12 (+3.15%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$3.94 +0.01 (+0.25%)

As of 08/1/2025 04:10 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Theratechnologies NASDAQ:THTX

$3.16 +0.01 (+0.32%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$3.16 -0.01 (-0.16%)

As of 08/1/2025 04:10 PM Eastern

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time